
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 27, 2007

NEKTAR THERAPEUTICS
(Exact name of Registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	0-24006 (Commission File Number)	94-3134940 (IRS Employer Identification No.)
---	--	--

201 Industrial Road
San Carlos, California 94070
(Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: (650) 631-3100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 27, 2007, the Board of Directors of Nektar Therapeutics (the "Company") appointed Mr. Lutz Lingnau as a new director to fill the vacancy created by resolution of the Board of Directors to increase the authorized number of directors from 9 to 10. Mr. Lingnau will serve until the 2010 annual meeting of stockholders or until his successor is duly elected and qualified. On August 29, 2007, the Company issued a press release announcing the appointment of Mr. Lingnau, a copy of which is included as Exhibit 99.1 to this filing.

Mr. Lingnau, age 64, retired from Schering AG Group, Germany, in 2005 as a member of Schering AG's Executive Board and as Vice Chairman, President and Chief Executive Officer of Schering Berlin, Inc., a United States subsidiary. Prior to his retirement, Mr. Lingnau was responsible for Schering AG's worldwide specialized therapeutics and dermatology businesses. He joined Schering AG's business trainee program in 1966. Throughout his career at Schering AG, he served in various capacities and in a number of subsidiaries in South America and the United States, including his roles as President of Berlex Laboratories, Inc., from 1983 to 1985, as the Head of Worldwide Sales and Marketing in the Pharmaceutical Division of Schering AG, from 1985 to 1989, and as Chairman of Berlex Laboratories, Inc. from 1985 to 2005. Mr. Lingnau is currently a member of the Supervisory Board of LANXESS AG, Chairman of the Board of Directors of Micropharma Limited, a biotechnology company, and was a member of the Board of Directors of Sirna Therapeutics, Inc., a biotechnology company, from February 2006 through the closing of the acquisition of Sirna by Merck & Co., Inc. in December 2006.

There are no arrangements or understandings between Mr. Lingnau and any other persons pursuant to which he was selected as a director. Mr. Lingnau will participate in the Company's Amended and Restated Compensation Plan for Non-Employee Directors filed by the Company on February 23, 2007 with the Securities and Exchange Commission on a Current Report on Form 8-K. Mr. Lingnau is not a party to any transaction with the Company that would require disclosure

under Item 404(a) of Securities and Exchange Commission's Regulation S-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit	No.	Description
99.1		Press release titled "Nektar Therapeutics Appoints Lutz Lingnau as New Board Member."

SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

By: /s/ Gil M. Labrucherie

Gil M. Labrucherie
Senior Vice President, General
Counsel and Secretary

Date: August 29, 2007

News ReleaseNecktar Therapeutics
650-631-3100 Phone150 Industrial Road
650-631-3150 FaxSan Carlos, CA
www.nektar.com

Nektar Therapeutics Appoints Lutz Lingnau as New Board Member

San Carlos, Calif., August 29, 2007 --- Nektar Therapeutics (Nasdaq: NKTR) announced today that Mr. Lutz Lingnau has been appointed to serve on its board of directors. Lingnau is a highly-respected pharmaceutical industry leader with over 35 years of experience in corporate management, product development and marketing.

"Lutz Lingnau brings to Nektar extensive pharmaceutical development and commercialization experience at an important point in the company's evolution," said Howard W. Robin, President and CEO of Nektar. "As we continue to drive our proprietary programs through the clinic, it is imperative that we leverage the strategic guidance of leaders like Lutz who have a proven track record of bringing successful therapeutics to market."

Most recently, Lingnau was a member of the Executive Board at Schering AG and Vice Chairman, President and CEO of Schering Berlin, Inc. While at Schering AG, he was responsible for the worldwide specialized therapeutics business and also held a number of other executive positions including Head of Worldwide Sales and Marketing in the Pharmaceutical Division, and Chairman and President of Berlex Laboratories, Inc.

"Nektar's innovative development of therapeutics using its proprietary PEGylation and pulmonary technologies is among the most important areas in biopharmaceutical drug development," Lingnau said. "I look forward to working with Howard and his executive team as they move Nektar's clinical pipeline forward and advance the company's strategic business objectives."

Lingnau is also currently a member of the Supervisory Board of LANXESS AG, Germany and Chairman of the Board of Directors of Micropharma Ltd., Montreal. He was formerly a member of the Board of Directors of Sirna Therapeutics, which was acquired by Merck & Co., Inc. in December 2006.

About Nektar

Nektar Therapeutics is a biopharmaceutical company with a mission to develop and enable differentiated therapeutics with its industry-leading pulmonary and PEGylation technology platforms. Nektar pulmonary and PEGylation technology, expertise, manufacturing capabilities and know-how have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its pulmonary and PEGylation technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements that reflect the company's current views as to its management team, board of directors, revenue potential, product pipeline potential and business prospects. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) the company's proprietary product candidates and those of certain of its partners are in the early phases of clinical development and the risk of failure is high and can occur at any stage prior to regulatory approval, (ii) the company's or its partner's ability to obtain regulatory approval for product candidates, (iii) the success of the company's partners in sales and marketing efforts to generate from approved products and future products (if any), and (iv) the company's patent applications for its technology platforms and proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future. Important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Tim Warner (650) 283-4915 or twarner@nektar.com (investors)

Stephan Herrera (415) 488-7699 or sherrera@nektar.com (investors)

Jennifer Ruddock (650) 631-4954 or jruddock@nektar.com (media)

#